Table of Content

25 April 2021, Volume 13 Issue 2 Previous Issue    Next Issue

Select

Research progress on the effect of general anesthetics on cancer metastasis and recurrence PEI Shenglin, JING Ren, PAN Linghui 2021, 13 (2):  113-120.  doi: 10.3969/j.issn.1674-5671.2021.02.01 Abstract ( 377 )   PDF (501KB) ( 825 )   Save Related Articles | Metrics

Select

New progress and prospect of targeted therapy for endometrial cancer LIU Shaoying, FAN Dian, ZHENG Bohao, ZHOU Shengtao 2021, 13 (2):  121-125.  doi: 10.3969/j.issn.1674-5671.2021.02.02 Abstract ( 808 )   PDF (448KB) ( 846 )   Save Related Articles | Metrics

Select

A comparative study on clinical diagnosis and treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in China AN Lan, RAN Xianhui, ZHENG Rongshou, CHEN Ru, WANG Shaoming, SUN Kexin, LEI Lin, ZENG Hongmei, WEI Wenqiang, ZHANG Min, ZHANG Siwei 2021, 13 (2):  126-132.  doi: 10.3969/j.issn.1674-5671.2021.02.03 Abstract ( 743 )   PDF (456KB) ( 455 )   Save Objective  To analyze the clinical diagnosis and treatment of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) from various clinical centers in China, and to provide the evidence for prevention and treatment measures. Methods The studied objects were gathered from new HCC or ICC cases diagnosed/treated for the first time in 33 hospitals in 12 provinces and cities from 2016 to 2017. The basic information, risk factors, clinical diagnosis and treatment information were collected, and the distribution characteristics of HCC and ICC were compared. Results A total of 3, 258 liver cancer patients HCC were collected, including 2, 671 males (81.98%) and 587 females (18.02%), with 2, 928 HCC patients (89.87%) and 330 ICC patients (10.13%). In both HCC and ICC patients, the proportion of males were higher than that of females, and the urban patients were more than the rural patients. The mean onset ages of HCC and ICC were (56.44±11.65) and (61.20±10.92) years, respectively. In HCC patients, the proportions of patients with smoking history (43.64% vs 33.44%, P=0.0004), with alcohol drinking history (31.14% vs 22.15%, P=0.0008), with a history of liver related disease (67.74% vs 34.16%, P<0.0001) and hepatitis B virus carriers(79.37% vs 64.55%, P=0.0002)were all higher than those in ICC patients. The proportions of HCC patients at early stage (Ⅰ-Ⅱ stage) and advanced stage (Ⅲ-Ⅳ stage) were 44.10% and 55.90%, respectively, while those of ICC patients were 17.01% and 82.99%, respectively, with statistically significant differences (P<0.0001). The main treatment options for HCC and ICC patients were surgery, interventional therapy and chemotherapy, the ratios of surgery were 60.64% and 45.31%, respectively; the ratios of interventional treatment were 23.86% and 21.50%, respectively; the ratios of chemotherapy were 22.13% and 24.77%, respectively. Conclusions The distribution characteristics of the HCC and ICC patients in China are different, and the proportion of advanced stage at the first diagnosis is high, and the main treatment options are surgery, interventional treatment and chemotherapy. HCC is the most common type of liver cancer, the prevention and control of liver cancer should be focused on male, middle?aged and elderly people. Related Articles | Metrics

Select

An analysis of epidemiological characteristics and developing trend of liver cancer incidence and mortality in Gansu cancer registration areas,2009—2015 ZHANG Jie, HUANG Yu, DING Gaoheng, CHEN Lili, WU Jianjun, LIU yuqin 2021, 13 (2):  132-137.  doi: 10.3969/j.issn.1674?5671.2021.02.04 Abstract ( 112 )   PDF (560KB) ( 144 )   Save  Objective To analyze the epidemiological characteristics of liver cancer incidence and mortality in Gansu cancer registration areas from 2009 to 2015, and to provide the evidence for the prevention and treatment strategies of liver cancer. Methods The data reported by 10 cancer registries in Gansu Province were collected, based on the auditing method developed by National Central Cancer Registry, as sample data to describe the distribution of incidence and mortality of liver cancer in Gansu Province. Stratified by areas (both urban and rural), gender and age groups, the crude incidence and mortality, age?standardized rate by Chinese standard population (ASR China), age?standardized rate by Segi's population (ASR world), cumulative rate, the changing trend of incidence and mortality and other indicators were calculated. Results From 2009 to 2015, there were 7, 457 new cases of liver cancer in Gansu cancer registration areas, with the crude incidence rate of 19.63/105, ASR China of 17.36/105, and ASR world of 19.56/105, ranking the third in the incidence of all malignant tumors. A total of 3, 279 death cases of liver cancer, with the crude mortality rate of 16.48/105, ASR China of 15.04/105, and ASR world of 17.36/105, ranked the fourth among all malignant tumor deaths. Both the incidence and mortality of liver cancer increased with the age, and reached the peak in 85+ age group which was higher in rural areas than in urban areas; and in males than in females. The incidence of liver cancer in Gansu Province from 2009 to 2015 showed an upward trend, with annual percent change (APC) of 2.5% (t=1.0, P=0.4); the mortality showed a downward trend, with APC of -3.7% (t=-1.1, P=0.3）. Conclusions The incidence of liver cancer in Gansu cancer registration areas shows an increase, and the mortality shows a decrease. The rural areas and male populations are the key targets for intervention. Related Articles | Metrics

Select

Analysis of incidence and mortality of liver cancer in cancer registration areas in Guangxi,2010—2016 LI Qiulin, CAO Ji, RONG Minhua, ZHOU Zihan, YU Hongping, GE Lianying, YU Jiahua 2021, 13 (2):  138-143.  doi: 10.3969/j.issn.1674-5671.2021.02.05 Abstract ( 341 )   PDF (563KB) ( 531 )   Save Objective To analyze the characteristics and trends of the incidence and mortality of liver cancer in the cancer registration areas in Guangxi from 2010 to 2016, and to provide the basis for developing the prevention and control measures of liver cancer in Guangxi. Methods The incidence and mortality data of cancer in the cancer registration areas in Guangxi from 2010 to 2016 were collected, and the incidence rate, mortality rate, proportionate, cumulative rate (0-74 years old) and truncated rate (35-64 years old) were calculated by areas (urban/rural), gender and age stratification. The age?standardized rates were calculated by the 2000 national census (ASR China) and Segi's standard population(ASR world). The trend of incidence and mortality of liver cancer was analyzed by Joinpoint model. Results From 2012 to 2016, the incidence of liver cancer in Guangxi was 41.79/105, the ASR China 34.86/105, the ASR world 33.45/105, the cumulative rate (0-74 years old) 3.79%, and the truncated rate (35-64 years old) 68.60/105. The mortality rate was 34.56/105, the ASR China 28.63/105, the ASR world 27.63/105, the cumulative rate (0-74 years old) 3.12%, and the truncated rate (35-64 years old) 54.48/105. The incidence and mortality rates of males were higher than those of females, and those in rural areas were higher than those in urban areas. From 2010 to 2016, the incidence and mortality levels of liver cancer in Guangxi cancer registration areas showed a significantly increasing trend, with the incidence and mortality APC of 5.38% (95%CI: 2.56%-8.29%, P<0.05) and 9.23% (95%CI:3.83%-14.92%, P<0.05), respectively. Conclusions From 2010 to 2016, the incidence and mortality of liver cancer in Guangxi cancer registration areas showed an increasing trend. Therefore, effective measures should be taken to prevent and control liver cancer according to the pathogenic factors and epidemic characteristics of liver cancer. Men aged 35 and above (especially in rural areas) are the key population for early screening and intervention. Related Articles | Metrics

Select

An analysis of incidence and mortality of liver cancer in the registries of Hebei Province,2012—2016 LIU Yanyu, QU Feng, LI Daojuan, LIANG Di, SHI Jin, WU Mengxuan, HE Yutong 2021, 13 (2):  143-149.  doi: 10.3969/j.issn.1674-5671.2021.02.06 Abstract ( 353 )   PDF (1079KB) ( 397 )   Save Objective To analyze the incidence and mortality of liver cancer in Hebei Province and its trend of change, and to provide a scientific basis for the prevention and treatment of liver cancer. Methods The incidence and mortality data of liver cancer obtained from 27 cancer registries of Hebei Province from 2012 to 2016 were collected, and analyzed by areas(urban/rural), gender and age groups. The 2000 national census and Segi's standard population were used to calculate the age?standardized rates. The trends of incidence and mortality of liver cancer in Cixian and Shexian were analyzed by Joinpiont model. Results From 2012 to 2016, a total of 12, 906 cases of liver cancer and 11, 522 deaths were reported in Hebei Province, with a crude incidence and mortality rate of 20.16/105 and 18.00/105, respectively. The incidence and mortality rate of liver cancer had decreased to a certain extent in Hebei Province, with the largest decrease among female and the urban population. The incidence and mortality rate of liver cancer in Cixian and Shexian showed a long?term decrease, but there was still a fluctuation. Conclusions The burden of liver cancer is still serious in Hebei Province, but its incidence and mortality are decreasing. The prevention of liver cancer in rural residents and males should be enhanced for early detection and treatment. Related Articles | Metrics

Select

An analysis of incidence and mortality of liver cancer in the registries of Heilongjiang Province from 2013 to 2017 SUN Huixin, ZHANG Maoxiang, WANG Wanying, JIA Haihan, LAN Li, SONG Bingbing 2021, 13 (2):  149-154.  doi: 10.3969/j.issn.1674-5671.2021.02.07 Abstract ( 260 )   PDF (583KB) ( 489 )   Save Objective To analyze the incidence and mortality of liver cancer in cancer registration areas of Heilongjiang Province and the trend of change. Methods The incidence and mortality data of liver cancer in the cancer registration areas of Heilongjiang Province from 2013 to 2017 were collected, and the incidence (mortality) rate, age-standardized incidence (mortality) rate and cumulative rate (0-74 years old) were calculated. The ASR was calculated based on the Chinese population census in 2000(ASR China) and Segi's world (ASR world) standard population. Annual percentage change (APC) was calculated by Joinpoint software. Results From 2013 to 2017, the incidence of liver cancer in the cancer registration areas of Heilongjiang Province was 29.13/105, the ASR China 17.18/105, and the cumulative rate (0-74 years old) 1.96%. The incidence of liver cancer in males (42.59/105) was higher than that in females (15.90/105), and the incidence of liver cancer in rural areas (35.05/105) was higher than that in urban areas (26.75/105). From 2013 to 2017, the mortality rate of liver cancer was 26.53/105, the ASR China 15.90/105, and the cumulative rate (0-74 years old) 1.78%. The mortality rate of liver cancer in males (38.33/105) was higher than that in females (14.93/105), and the mortality rate of liver cancer in rural areas (30.65/105) was higher than that in urban areas (24.88/105). From 2013 to 2017, the ASR China incidence showed a downward trend, while ASR China mortality showed no significant trend (P>0.05), and the male ASR China incidence showed a significant downward trend(P<0.05). Conclusions The burden of liver cancer in Heilongjiang Province is relatively heavy, the incidence rate is decreasing, and the mortality is relatively stable. More attention should be paid to male and rural areas with comprehensive prevention and controlling measures. Related Articles | Metrics

Select

Analysis of incidence and mortality of liver cancer in Shanxi cancer  registries,2016 GUO Xuerong, MA Zhaohui, CAO Ling, WANG Xinchen, ZHANG Ruifeng, SU Fang, ZHANG Yongzhen 2021, 13 (2):  155-163.  doi: 10.3969/j.issn.1674-5671.2021.02.08 Abstract ( 220 )   PDF (493KB) ( 403 )   Save Objective To analyze the incidence and mortality of liver cancer in Shanxi cancer registries in 2016, and to provide the strategies of prevention and treatment of liver cancer. Methods The incidence and mortality data of liver cancer in 12 cancer registries of Shanxi Province were collected with recording the incidence, mortality. The age-standardized of Chinese standard population (ASR China) and world standard population (ASR world) were calculated by the Chinese standard population in 2000 and Segi's population, respectively. The incidence and mortality rates of liver cancer were analyzed based on the stratification of the gender , age and areas (urban and rural). Results In 2016, 754 new cases of liver cancer were recorded in Shanxi cancer registries, with the incidence of 15.42/105 (male: 19.40/105, female: 11.29/105), ASR China of 10.72/105 and the ASR world of 10.75/105. The incidence in urban areas was 10.14/105, and ASR China was 6.73/105; the incidence in rural areas was 19.00/105, and ASR China was 13.48/105. A total of 761 cases died of liver cancer in Shanxi cancer registries, with the mortality rate of 15.56/105 (male: 19.80/105, female: 11.17/105), ASR China of 10.71/105 and the ASR world of 10.86/105. The mortality rate of urban areas was 14.90/105, and ASR China was 9.86/105; the mortality rate of rural areas was 16.01/105, and ASR China was 11.37/105. The incidence and mortality of liver cancer both increased with age, and the incidence increased more significantly after the age of 35. The incidence and mortality in Shanxi Province reached the peak in the age group of 80 years and 85 years, respectively, and the male was higher than the female. Conclusions The incidence and mortality rates of liver cancer in Shanxi cancer registries are lower than the national average, the male is higher than the female, and higher in rural areas than in urban areas. Therefore, the prevention and treatment of liver cancer should focus on males and people in rural areas. Related Articles | Metrics

Select

An analysis of incidence and mortality of liver cancer in Fujian cancer registries,2017 LIN Yongtian, MA Jingyu, XIANG Zhisheng, JIANG Huijuan, ZHOU Yan 2021, 13 (2):  164-169.  doi: 10.3969/j.issn.1674-5671.2021.02.09 Abstract ( 404 )   PDF (446KB) ( 491 )   Save Objective To analyze the incidence and mortality data of liver cancer in Fujian registration areas in 2017, and to provide scientific basis for the formulation and evaluation of liver cancer prevention and treatment strategies. Methods According to the data review and evaluation method developed by National Central Cancer Registry, the 2017 data reported by 12 cancer registries in Fujian Province were evaluated, among which the data from 10 registries that met the requirements were merged and analyzed. Stratified by areas (urban/rural), gender and age groups, the crude incidence and mortality, standardized rate and cumulative rate (0-74 years) were calculated. The age-standardized rate by Chinese standard population (ASR China)was calculated according to the Chinese standard population in 2000 and the age-standardized rate by world standard population (ASR world) was calculated according to the Segi's population. Results The 10 cancer registries in Fujian Province in 2017 covered a total of 6, 588, 959 registered population, of which urban and rural areas accounted for 43.89% and 56.11%, respectively. In 2017, the incidence of liver cancer in Fujian cancer registration areas was 31.14/105 (male: 48.02/105, female: 13.70/105), with ASR China of 22.51/105 and ASR world of 21.70/105.  The incidence rate in rural areas (ASR China: 23.87/105, ASR world: 22.90/105) was higher than that in urban areas (ASR China: 20.81/105, ASR world: 20.16/105). In 2017, the mortality rate of liver cancer in Fujian cancer registration areas  was 28.09/105 (male: 43.78/105, female: 11.88/105), with ASR China of 20.04/105 and ASR world of 19.45/105. The mortality rate in rural areas (ASR China: 20.91/105, ASR world: 20.18/105) was higher than that in urban areas (ASR China: 18.99/105, ASR world: 18.56/105). Conclusions The prevalence of liver cancer in Fujian Province shows differences in region and gender, and the targeted prevention and control should be carried out from the aspects of primary and secondary preventions.【 Related Articles | Metrics

Select

Effect of silencing IGFBP?1 on the growth of human gastrointestinal stromal tumor cells GIST882 and its mechanism ZHU Xianzhang, TIAN Weili, TIAN Peili, LI Tao 2021, 13 (2):  170-176.  doi: 10.3969/j.issn.1674-5671.2021.02.10 Abstract ( 270 )   PDF (2275KB) ( 129 )   Save Objective To investigate the expression of insulin-like growth factor binding protein 1 (IGFBP-1) in human gastrointestinal stromal tumors, and its effect on the growth of gastrointestinal stromal tumor cells as well as its underlying mechanism. Methods The expression of IGFBP-1 was detected by immunohistochemical staining.The human gastrointestinal stromal tumor cells GIST882 were transfected with siRNA-NC (siRNA-NC group) and siRNA-IGFBP-1 (siRNA-IGFBP-1 group), respectively, and blank control group was set. The mRNA and protein expression level of IGFBP-1 were detected by qRT-PCR and the Western blot; the cell viability was detected by the CCK-8 experiment; the cell proliferation ability was detected by the EDU test; the cell apoptosis was detected by Annexin V-FITC/PI staining; the cell migration and invasion ability was detected by Transwell chamber experiment, and the expression of PI3K/AKT/mTOR signaling pathway-related proteins was detected by the Western blot. Results The positive expression rate of IGFBP-1 in gastrointestinal stromal tumor tissues was higher than that in adjacent tissues (P<0.05). Compared with the blank control group and the siRNA-NC group, the relative expression of IGFBP-1 mRNA and protein in siRNA-IGFBP-1 group were decreased (all P<0.05). After IGFBP-1 silencing, the cell proliferation activity decreased, the EDU positive cells rate decreased, the apoptosis rate increased, and the number of migrating and invading cells decreased (both P<0.05); and the ratios of p-PI3K/PI3K, p-AKT/AKT and p-mTOR/mTOR decreased (all P<0.05). Conclusions Silencing IGFBP-1 expression can inhibit the cell proliferation, migration, invasion of gastrointestinal stromal tumor, and promote cell apoptosis, which may be related to the inhibition of PI3K/AKT /mTOR signal pathway activation. Related Articles | Metrics

Select

Effect of lncRNA ZEB1?AS1 on the proliferation and apoptosis of B?cell non?Hodgkin's lymphoma and analysis of its downstream regulatory network LIAO Chengcheng, DENG Muying, MO Guojun, LEI Danqing, XIA Aijun, RONG Chao, TAN Xiaohong, CEN Hong, LU Shengjuan 2021, 13 (2):  170-176.  doi: 10.3969/j.issn.1674-5671.2021.02.11 Abstract ( 106 )   PDF (3052KB) ( 347 )   Save Objective  To investigate the effects of long non-coding RNA(lncRNA) ZEB1-AS1 on the proliferation and apoptosis of B-cell non-Hodgkin's lymphoma(B-NHL), and to construct lncRNA, miRNA, mRNA-related competitive endogenous RNA (ceRNAs) network. Methods The Cox regression model was used to screen the lncRNAs related to the prognosis of diffuse large B-cell lymphoma (DLBCL) in the GEO data set (GSE31312). Lentiviral transfection technology was used to establish the ZEB1-AS1 knockdown B-NHL cell model, and the CCK-8 and flow cytometry were used to detect the proliferation and apoptosis of B-NHL cells after treated with ZEB1-AS1 knockdown and different concentrations (50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL) doxorubicin (Dox). The lncRNA-miRNA-mRNA ceRNA regulatory network was constructed with ZEB1-AS1 as the node, and GO, KEGG and PPI were used to analyze the core mRNA of related to the downstream of the regulatory network and its functions. Results A total of 20 high-risk lncRNAs were screened, and 4 miRNAs binding to ZEB1-AS1 and 1, 208 potential downstream mRNAs co-expressed with ZEB1-AS1 and combined with miRNAs were predicted, so as to construct the lncRNA-miRNA-mRNA regulatory network and the PPI regulatory network.In vitro experiments, knockdown of ZEB1-AS1 could significantly inhibit cell proliferation and promote cell apoptosis compared with the empty group (all P<0.05), and the combination of ZEB1-AS1 knockdown and Dox could synergistically inhibit the cell proliferation and promote the apoptosis. Conclusions ZEB1-AS1 knockdown can inhibit the proliferation and promote the apoptosis of B-NHL cells, enhancing the drug sensitivity of Dox.The ceRNA regulatory network constructed with ZEB1-AS1 as a node may be an important regulatory mechanism and diagnosis and treatment target for DLBCL. Related Articles | Metrics

Select

Fuzheng Yiliu decoction inhibits the proliferation,apoptosis and autophagy of non?small cell lung cancer through PI3K/Akt/mTOR signaling pathway MENG Dongxue, GUO Yurong, LUO Binjun, ZHOU Xinhua, FU Yao, CAO Tianxiong 2021, 13 (2):  177-182.  doi: 10.3969/j.issn.1674-5671.2021.02.12 Abstract ( 209 )   PDF (1504KB) ( 273 )   Save Objective To investigate the effects of Fuzheng Yiliu decoction on the proliferation, invasion, migration, apoptosis, autophagy and PI3K/Akt/mTOR signaling pathway of non-small cell lung cancer. Methods The non-small cell lung cancer A549 cells were cultured in vitro with different concentrations (12.5 mg/mL, 25 mg/mL, 50 mg/mL, 100 mg/mL, 200 mg/mL, 400 mg/mL) of Fuzheng Yiliu decoction, and the proliferation inhibition rate was determined by the CCK-8 assay; the invasion of cells was detected by Transwell assay; the cell migration was measured by the scratch test; the apoptosis rate was detected by the flow cytometry; the expression levels of autophagy-related proteins and PI3K/Akt/mTOR signaling pathway-related proteins were detected by the Western blot, and the formation of autophagy lysosome was observed under the transmission electron microscope. Results After treated with 200 mg/mL and 400 mg/mL of Fuzheng Yiliu decoction, the proliferation inhibition rate of A549 cells was increased (all P<0.05). After treated with 200 mg/mL of Fuzheng Yiliu decoction, the invasion and migration of A549 cells were decreased (all P<0.05); the apoptosis rate of A549 cells was increased (P<0.05); the expression levels of Beclin-1 and LC3Ⅱ/Ⅰ proteins were increased (all P<0.05), while the expression levels of P62 protein was decreased (P<0.05); the number of autophagy lysosomes increased in A549 cells; the expression levels of p-PI3K /PI3K, p-Akt /Akt, and p-MTOR /mTOR proteins were decreased (all P<0.05). Conclusions Fuzheng Yiliu decoction can inhibit the proliferation of A549 cells and promote cell apoptosis and autophagy, which may be related to the inactivation of PI3K/Akt/mTOR signaling pathway, and may be a potential drug for the treatment of non-small cell lung cancer. Related Articles | Metrics

Select

Association between polymorphisms in miRNA binding site of BRCA1 gene and overall survival of hepatocellular carcinoma after operation LIN Qiuling, LIU Yingchun, WEN Qiuping, ZHOU Zihan, JIANG Yanji, LIANG Xiumei, GONG Wenfeng, MA Liang, LIU Shuyan, YU Hongping 2021, 13 (2):  183-189.  doi: 10.3969/j.issn.1674-5671.2021.02.13 Abstract ( 271 )   PDF (487KB) ( 390 )   Save Objective To investigate the effect of single nucleotide polymorphism (SNP) in microRNA (miRNA) binding site of BRCA1 gene on the overall survival (OS) of patients with hepatocellular carcinoma (HCC) after operation. Methods A total of 363 HCC patients with undergone radical surgery resection in the Guangxi Medical University Cancer Hospital from June 2004 to December 2013 were included. The Cox proportional hazard model and the Kaplan-Meier method were used to analysis the association between polymorphisms in miRNA binding site of BRCA1 gene and OS of patients with HCC after operation. Results The SNP rs8176318(C>A) in the miRNA binding site of BRCA1 gene was significantly associated with the OS of HCC patients after operation. In the recessive model, after adjusting for hepatitis B virus (HBV) infection, BCLC stage, tumor diameter, tumor thrombus and other factors, the Cox regression analysis showed that HCC patients carrying rs8176318 AA genotypes had a significantly decreased risk of death when compared with those carrying CC/CA genotype (HR=0.675, 95%CI = 0.494-0.922, P=0.014). The Kaplan-Meier curve showed that the median OS of HCC patients with AA genotype was significantly longer than that with CC/CA genotype (46.1 months vs 33.8 months, P=0.049). Using the GTEX database for quantitative trait locus analysis, the rs8176318 A allele was associated with lower BRCA1 mRNA expression levels in liver tissues (P<0.001). Conclusions BRCA1 rs8176318 polymorphism is associated with a lower survival outcomes in patients with HCC after operation, and the A allele is associated with a lower risk of death after operation, but the result needs to be verified by a multi-center study with a larger sample size. Related Articles | Metrics

Select

Comparison of six staging systems for predicting the postoperative prognostic value of patients with AFP?negative hepatocellular carcinoma HU Xiaoyin, ZHANG Jie, ZHAO Jingfei, ZHAN Guohua, LI Yuankuan, XIANG Bangde 2021, 13 (2):  190-194.  doi: 10.3969/j.issn.1674-5671.2021.02.14 Abstract ( 339 )   PDF (490KB) ( 403 )   Save Objective To compare the values of Barcelona clinic liver cancer (BCLC), China liver cancer staging (CNLC), TNM staging system, Japanese integrated staging score (JIS), cancer of the liver Italian program (CLIP) and Okuda kunio staging system (Okuda) in the postoperative prognosis prediction of patients with serum alpha-fetoprotein (AFP)-negative hepatocellular carcinoma (HCC). Methods The clinicopathological data of AFP-negative HCC patients were retrospectively analyzed, who underwent hepatectomy at the Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, from January 2012 to December 2017 and met the inclusion criteria.The patients were staged according to the BCLC, CNLC, TNM, JIS, CLIP, and Okuda staging systems and followed up.The discrimination, stratification ability, and predictive value of the six staging systems were compared based on time-dependent receiver operating characteristic(ROC) curves, log-rank test, and likelihood ratio test. Results The area under ROC curves(AUC) of CNLC to predict the overall survival of HCC patients after surgery was 0.682, corresponding to a sensitivity of 0.655 and a specificity of 0.691 using stage Ⅱb as the cut point; the AUCs of CNLC staging to predict the survival at 1-, 3-, and 5-year were 0.670 (95%CI: 0.603-0.738), 0.575 (95%CI: 0.441-0.708), and 0.689 (95%CI: 0.407-0.971), respectively, which was better than those of other staging systems (all P<0.05).The log-rank test showed that all the six staging systems had a good risk stratification ability. The likelihood ratio test showed that CNLC had the highest value in predicting the overall survival (χ2=39.575, P=0.011). Conclusions Among the six staging systems, CNLC staging is the best staging system in predicting the prognosis of AFP-negative HCC patients after surgery. Related Articles | Metrics

Select

Prognostic value of modified Gustave Roussy Immune Score for patients with unresectable esophageal squamous cell carcinoma ZENG Yuting, SUN Xinchen 2021, 13 (2):  195-201.  doi: 10.3969/j.issn.1674-5671.2021.02.15 Abstract ( 357 )   PDF (655KB) ( 364 )   Save Objective  To evaluate the prognosis values of modified Gustave Roussy Immune Score (mGRIm-Score) for patients with unresectable esophageal squamous cell carcinoma (ESCC). Methods The data on lactic dehydrogenase, neutrophil/lymphocyte ratio and serum albumin of 150 patients with unresectable ESCC before chemoradiotherapy were collected . The optimal cut-off values were calculated by receiver operating characteristic(ROC) curves and the mGRIm-Score was constructed. The patients were divided into high mGRIm-Score group and low mGRIm-Score group according to the scoring criteria. Survival was analyzed by Kaplan-Meier method, and independent prognostic factors were analyzed by multivariable Cox regression. Results The median overall survival for high mGRIm-Score group and low mGRIm-Score group were 17.0 months (95%CI: 9.6-24.4 months ) and 48.0 months(95%CI: 38.9-57.1 months), respectively; the median progression-free survival were 12.0 months(95%CI :9.5-14.5 months) and 25.0 months (95%CI: 15.7-52.4 months), respectively, and the differences were statistically significant(all P<0.05). Multivariable analysis suggested that mGRIm-Score was an independent prognostic factor for overall survival (HR=1.626, 95%CI :1.1-2.5, P=0.024) and progression-free survival (HR=1.539, 95%CI :1.0-2.3, P=0.034) . Conclusions The mGRIm-Score before chemoradiotherapy can be used as a comprehensive indicator to evaluate the survival prognosis of patients with unresectable ESCC. Related Articles | Metrics

Select

Expression and clinical significance of connexin 26 in lung adenocarcinoma associated fibroblasts SONG Jinjing, WEI Tongtong, LIANG Kai, HUANG Zhiguang, CHEN Gang, MAO Naiquan, YANG Jie 2021, 13 (2):  201-206.  doi: 10.3969/j.issn.1674-5671.2021.02.16 Abstract ( 249 )   PDF (2070KB) ( 381 )   Save Objective To investigate the expression of connexin 26 (Cx26) in lung adenocarcinoma associated fibroblasts and its clinical significance. Methods The 6 cases of lung adenocarcinoma tissues and adjacent normal lung tissues that were surgically resected in Guangxi Medical University Cancer Hospital from November 2018 to May 2019 were collected, and the primary cancer-associated fibroblasts (CAFs) and normal lung fibroblasts (NLFs) were isolated.The primary fibroblasts were identified through the cell morphology observed by optical microscope, the expression level of cell biomarkers α-SMA, E-cadherin and Vimentin detected by the Western blot and immunofluorescence staining; the level of Cx26 mRNA was detected by qRT-PCR. The distribution and expression of Cx26 in 22 cases of lung adenocarcinoma and adjacent tissues collected from January 2013 to December 2018 were detected by immunofluorescence staining. Results The primary CAFs and NLFs were successfully isolated. The microscopy reported that CAFs and NLFs were spindle-shaped cells, both of which expressed α　-SMA and Vimentin, but only slightly expressed E-cadherin, and the expression level of α-SMA in CAFs was higher than that in NLFs (P<0.001).The qRT-PCR results showed that the expression level of Cx26 in CAFs showed a continuous downward trend with the increase of tumor stage(t=5.684, P=0.011). The immunofluorescence staining results showed that the expression of Cx26 in lung adenocarcinoma tissues was lower than that in normal lung tissues (t=2.609, P=0.016). Conclusions Downregulation of Cx26 expression in CAFs within tumor microenvironment may be associated with higher stage and progressive malignancy of lung adenocarcinoma. Related Articles | Metrics

Select

Application of hollow core “2” incision technique in oncoplastic surgery of breast cancer DONG Jie, DENG Zhihong, ZENG Jiajia, HUANG Yun, ZHUO Rui 2021, 13 (2):  207.  doi: 10.3969/j.issn.1674-5671.2021.02.17 Abstract ( 231 )   PDF (696KB) ( 389 )   Save Objective To investigate the effect of the clinical application of the hollow core “2” incision technique in oncoplastic surgery of breast cancer. Methods The clinical and follow-up data of 28 breast cancer patients who underwent hollow core “2”incision breast oncoplastic surgery in the department of Breast Surgery, Guilin TCM Hospital, from May 2017 to September 2018 were retrospectively analyzed, and the postoperative complications, aesthetic effect and recurrence were analyzed. Results The mean age of the 28 patients was 57.3 years, the mean hospital stay was 6 days, the mean weight of the resected tissue was 50.1 g, the maximum tumor size was 4.0 cm×3.2 cm, the minimum was 1.8 cm×2.0 cm, the mean operation time was 82 min, and the intraoperative median blood loss was 30.5 mL.One patient underwent a second positive margin resection.There were no complications such as seroma, fat liquefaction and tissue necrosis in all patients within 1 month after surgery.One year after surgery, the cosmetic effect was excellent in 18 cases, good in 8 cases, and general in 2 cases. There was no local recurrence in the 3-year follow-up. Conclusions The hollow core “2” incision breast oncoplastic surgery technique has good tumor safety and aesthetic results, which can provide a new method for breast oncoplastic surgery. Related Articles | Metrics

Select

Advances in metabolomics research of gastric cancer XIAN Qingying, WU Jun, LU Lu, YAN Haijiao, WANG Qi, ZHU Danxia 2021, 13 (2):  211-215.  doi: 10.3969/j.issn.1674-5671.2021.02.18 Abstract ( 555 )   PDF (324KB) ( 754 )   Save Related Articles | Metrics

Select

Advances in  IL?6/STAT3 signaling pathway in the development and treatment of colorectal cancer HE Ziqin, LIU Ziyu, SHE Xiaomin, LI Shuanghang, LU Lu, YE Jiazhou, LIANG Rong, LIN Yan 2021, 13 (2):  216-221.  doi: 10.3969/j.issn.1674-5671.2021.02.19 Abstract ( 447 )   PDF (777KB) ( 794 )   Save Related Articles | Metrics

Select

Research progress of exosomes in diagnosis and treatment of ovarian cancer LUO Yanlu, FAN Jiangtao, YANG Jiahuang 2021, 13 (2):  222-225.  doi: 10.3969/j.issn.1674-5671.2021.02.20 Abstract ( 358 )   PDF (309KB) ( 580 )   Save Related Articles | Metrics

Select

Research progress on the implementation and evaluation of humanistic care in tumor nursing CHANG Zhixue, CHEN Lijun 2021, 13 (2):  226-230.  doi: 10.3969/j.issn.1674-5671.2021.02.2 Abstract ( 492 )   PDF (353KB) ( 747 )   Save Related Articles | Metrics